NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









28bio

28bio

Private
New Orleans, LouisianaHealthcare & Life Scienceshttps://www.28bio.com/

Last Round

Pre-Series A3

Jun 24, 2025

Est. Valuation

$20.01M

Total Funding Raised

$9.03M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

28bio is a neurotechnology company that provides a platform to engineer human brain and nerve models for accelerating drug discovery for neurological diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Biotech Equipment, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts, Hardware Sales

AI Layer

Application

Keywords

brain-on-a-chipbrain organoidspreclinical testingalternative to animal testingneurotechnology platformCRO servicesneurological disease modelingdrug discovery platformneurotoxicity screeningorganoid intelligenceiPSC-derived organoidsAI drug discoveryhigh-throughput screening3D cell culturein vitro models

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

28bio Comparables

Compare 28bio with similar companies based on industry and business-model similarity.

28bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Emulate
85%
Hesperos Inc.
83%
Synaxys
82%

28bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Pre-Series A3Jun 24, 2025
Series A ExtensionJun 10, 2021
GrantNov 2, 2020
SeedJun 15, 2020
GrantSep 21, 2017
Pre Seed
Aug 3, 2017

Key People

Founding team and executive leadership

Gregory Kading

Consulting CFO

Executive Team

28bio Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 20, 2026

    Open roles increased to 5, 2.1x the trailing average.

  • Apr 16, 2026

    Monthly visitors increased 406% MoM, from 422 to 2.1K.

28bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

28bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about 28bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersNew Orleans, Louisiana
Employee Range23
Year Founded2014
Last FundingJun 24, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.